Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

Discovery of new thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives as orally active phosphoinositide 3-kinase inhibitors.

Yan Sun | Rong Fu | Songwen Lin | Jingbo Zhang | Ming Ji | Yan Zhang | Deyu Wu | Kehui Zhang | Hua Tian | Mingyi Zhang | Li Sheng | Yan Li | Jing Jin | Xiaoguang Chen | Heng Xu
Bioorganic & medicinal chemistry | 2021

As abnormal PI3K signaling is a feature of many types of cancer, the development of orally active PI3K inhibitors is of great significance for targeted cancer therapy. Through integrating strategies of reducing aromatic character/increasing the fraction of sp3 carbons together with scaffold hopping, we designed and synthesized two new series of thieno[2,3-d]pyrimidine and thiazolo[5,4-d]pyrimidine derivatives for use as PI3K inhibitors. Our structure-activity relationship studies led to the identification of thieno[2,3-d]pyrimidine 6a and thiazolo[5,4-d]pyrimidine 7a, which exhibited remarkable nanomolar PI3K potency, good antiproliferative activity, favorable pharmacokinetic properties and significant in vivo anti-cancer efficacy. Notably, thiazolo[5,4-d]pyrimidine 7a had better anti-cancer activity than thieno[2,3-d]pyrimidine 6a and is worthy of further pre-clinical evaluation for its use in cancer treatment.

Pubmed ID: 33285407

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


NU/J (tool)

RRID:IMSR_JAX:002019

Mus musculus with name NU/J from IMSR.

View all literature mentions

BALB/cAnNCrl (tool)

RRID:MGI:2683685

laboratory mouse with name BALB/cAnNCrl from MGI.

View all literature mentions

HGC-27 (tool)

RRID:CVCL_1279

Cell line HGC-27 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

NCI-H292 (tool)

RRID:CVCL_0455

Cell line NCI-H292 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

NCI-H23 (tool)

RRID:CVCL_1547

Cell line NCI-H23 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

MDA-MB-231 (tool)

RRID:CVCL_0062

Cell line MDA-MB-231 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

MG-63 (tool)

RRID:CVCL_0426

Cell line MG-63 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

NCI-H358 (tool)

RRID:CVCL_1559

Cell line NCI-H358 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

A-549 (tool)

RRID:CVCL_0023

Cell line A-549 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

NCI-H460 (tool)

RRID:CVCL_0459

Cell line NCI-H460 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions

MGC-803 (tool)

RRID:CVCL_5334

Cell line MGC-803 is a Cancer cell line with a species of origin Homo sapiens (Human)

View all literature mentions